Published in Vaccine on November 25, 2004
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol (2010) 4.06
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med (2012) 1.84
Applications of nanotechnology for immunology. Nat Rev Immunol (2013) 1.65
Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol (2006) 1.15
Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11
Development of therapeutic HPV vaccines. Lancet Oncol (2009) 1.04
Targeted treatments for cervical cancer: a review. Onco Targets Ther (2012) 1.00
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother (2012) 0.97
Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev (2008) 0.96
Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96
Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun (2014) 0.95
HPV infection: immunological aspects and their utility in future therapy. Infect Dis Obstet Gynecol (2013) 0.89
New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) (2011) 0.89
Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. Nat Rev Cancer (2015) 0.88
Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol (2014) 0.86
Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol J (2009) 0.85
Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. Vaccine (2007) 0.84
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev Vaccines (2016) 0.82
Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother (2016) 0.82
Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy. PLoS One (2013) 0.81
Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol (2011) 0.81
Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. Clin Vaccine Immunol (2015) 0.80
CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses. Biomed Res Int (2013) 0.79
Progress in the development of a cervical cancer vaccine. Ther Clin Risk Manag (2006) 0.78
Potential anti-HPV and related cancer agents from marine resources: an overview. Mar Drugs (2014) 0.76
Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability. PLoS One (2016) 0.75
Moving forward with human papillomavirus immunotherapies. Hum Vaccin Immunother (2016) 0.75
Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med (2009) 5.46
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst (2004) 2.79
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Chapter 8: Screening for cervical cancer in developing countries. Vaccine (2006) 2.35
Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci (2011) 2.31
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res (2005) 2.24
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer (2011) 2.09
Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets (2010) 1.91
Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol (2007) 1.66
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine (2008) 1.52
Clearance of human papillomavirus in women treated for cervical dysplasia. Obstet Gynecol (2011) 1.45
A new prognostic model for FIGO stage 1 epithelial ovarian cancer. Gynecol Oncol (2006) 1.43
Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine (2008) 1.40
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res (2012) 1.39
Secondary acylation of Klebsiella pneumoniae lipopolysaccharide contributes to sensitivity to antibacterial peptides. J Biol Chem (2007) 1.33
Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis (2005) 1.30
An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics (2003) 1.30
Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumors. Int J Gynecol Cancer (2013) 1.25
Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem (2013) 1.10
Tentorial dural arteriovenous fistulae: operative strategies and microsurgical results for six types. Neurosurgery (2008) 1.05
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
Pontocerebellar hypoplasia type 6: A British case with PEHO-like features. Am J Med Genet A (2010) 1.02
Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. J Ovarian Res (2012) 1.02
Microwave tomography of extremities: 2. Functional fused imaging of flow reduction and simulated compartment syndrome. Phys Med Biol (2011) 1.01
Macrophages are mediators of gastritis in acute Helicobacter pylori infection in C57BL/6 mice. Infect Immun (2008) 1.01
The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol (2006) 1.00
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res (2004) 1.00
Single coronary artery. J Am Coll Cardiol (2009) 1.00
Microwave tomography of extremities: 1. Dedicated 2D system and physiological signatures. Phys Med Biol (2011) 0.99
ISCOM-based vaccines: the second decade. Immunol Cell Biol (2005) 0.98
Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study. Int J Gynecol Cancer (2010) 0.96
Neuroendocrine and behavioral effects of embryonic exposure to endocrine disrupting chemicals in birds. Brain Res Rev (2007) 0.95
Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study). BMC Cancer (2013) 0.94
Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J Cell Biochem (2002) 0.93
Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children. Influenza Other Respir Viruses (2009) 0.92
Early phase II trial of human rotavirus vaccine candidate RV3. Vaccine (2002) 0.89
Outcome in women with no endocervical component on cervical cytology after treatment for high-grade cervical dysplasia. Aust N Z J Obstet Gynaecol (2009) 0.88
Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol (2006) 0.87
FIGO Cancer Report 2012. Int J Gynaecol Obstet (2012) 0.87
Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: a multinational collaborative study (ANZGOG0801). Gynecol Oncol (2012) 0.87
Long-term antibody and immune memory response induced by pulmonary delivery of the influenza Iscomatrix vaccine. Clin Vaccine Immunol (2011) 0.87
Expenditure and resource utilisation for cervical screening in Australia. BMC Health Serv Res (2012) 0.86
ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine (2004) 0.86
Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. Support Care Cancer (2015) 0.86
Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach. Proteomics (2003) 0.85
Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine (2009) 0.85
Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium. Clin Cancer Res (2003) 0.84
An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms. Dev Med Child Neurol (2013) 0.84
Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clin Immunol (2013) 0.84
Helicobacter pylori thiolperoxidase as a protective antigen in single- and multi-component vaccines. Vaccine (2012) 0.84
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer (2014) 0.84
Screening for depression and anxiety in women with breast and gynaecologic cancer: course and prevalence of morbidity over 12 months. Psychooncology (2013) 0.83
Control of pandemic (H1N1) 2009 influenza virus infection of ferret lungs by non-adjuvant-containing pandemic and seasonal vaccines. Vaccine (2012) 0.83
Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int J Gynecol Cancer (2010) 0.83
Targeting subcapsular antigens for prevention of Klebsiella pneumoniae infections. Vaccine (2008) 0.83
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. Gynecol Oncol (2004) 0.83
CD8+ T cells are associated with severe gastritis in Helicobacter pylori-infected mice in the absence of CD4+ T cells. Infect Immun (2007) 0.82
Complementary medicine use by Australian women with gynaecological cancer. Psychooncology (2006) 0.82
Targeting gene expression to endothelium in transgenic animals: a comparison of the human ICAM-2, PECAM-1 and endoglin promoters. Xenotransplantation (2003) 0.82
Excessive bleeding and transfusion in a prior cardiac surgery is associated with excessive bleeding and transfusion in the next surgery. Anesth Analg (2006) 0.82
Persistent trophoblast disease following partial molar pregnancy. Aust N Z J Obstet Gynaecol (2006) 0.82
Re-transplantation after bortezomib-based therapy. Br J Haematol (2011) 0.82
Cotyledonoid dissecting leiomyoma. Pathology (2003) 0.82
Should the Pap smear be repeated at the first colposcopy visit? Aust N Z J Obstet Gynaecol (2005) 0.82
A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer. Clin Cancer Res (2003) 0.81
Sister Society Meeting on Global Education Development and Collaboration: Meeting Report. Int J Gynecol Cancer (2016) 0.81
Hereditary gynecologic cancers. Int J Gynaecol Obstet (2013) 0.80
Question 1: Should steroids be used to treat abdominal pain caused by Henoch-Schonlein purpura? Arch Dis Child (2012) 0.80
Guidelines following hydatidiform mole: a reappraisal. Aust N Z J Obstet Gynaecol (2006) 0.79
Impact of manufacturing improvements on clinical safety of albumin: Australian pharmacovigilance data for 1988-2005. Crit Care Resusc (2006) 0.79
Extensor retinaculum of the wrist: gross anatomical correlation with MR imaging after ultrasound-guided tenography with emphasis on anatomical features in wrist dorsiflexion responsible for tendon impingement. Skeletal Radiol (2013) 0.78
Women with low-grade abnormalities on Pap smear should be referred for colposcopy. Aust N Z J Obstet Gynaecol (2004) 0.78
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. Transfusion (2014) 0.78
Should liquid-based cytology be performed prior to colposcopy? A comparison of the accuracy, unsatisfactory rates and cost in a tertiary referral setting. Aust N Z J Obstet Gynaecol (2009) 0.78
Evaluation of superoxide dismutase from Helicobacter pylori as a protective vaccine antigen. Vaccine (2010) 0.78
Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy. Cancers (Basel) (2012) 0.77
Findings and Outcomes in a Prevaccination Cohort of Women Younger Than 25 Years Attending a Tertiary Colposcopy Service. J Low Genit Tract Dis (2016) 0.77
Demographic variables routinely collected at colposcopic examination do not predict who will default from conservative management of cervical intraepithelial neoplasia I. Aust N Z J Obstet Gynaecol (2005) 0.77
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era. Int J Gynecol Cancer (2013) 0.77
Glycosylation of pilin and nonpilin protein constructs by Pseudomonas aeruginosa 1244. J Bacteriol (2010) 0.77
"Like roulette": Australian women's explanations of gynecological cancers. Soc Sci Med (2005) 0.77
Association of antigens to ISCOMATRIX adjuvant using metal chelation leads to improved CTL responses. Vaccine (2004) 0.76
Reproductive consequences of EDCs in birds: what do laboratory effects mean in field species? Neurotoxicol Teratol (2002) 0.76
Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature (2015) 0.75
ISCOMATRIX™ adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza. Hum Vaccin Immunother (2015) 0.75
Risk stratification for free. Br J Gen Pract (2016) 0.75
Partnership for Healthier Asians: Disseminating Evidence-Based Practices in Asian-American Communities Using a Market-Oriented and Multilevel Approach. JMIR Res Protoc (2016) 0.75
Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations. J Transl Med (2014) 0.75
Challenging Salpingectomy as a Risk-Reducing Measure for Ovarian Cancer: Histopathological Analysis of the Tubo-Ovarian Interface in Women Undergoing Risk-Reducing Salpingo-oophorectomy. Int J Gynecol Cancer (2017) 0.75
Treatment decisions: a qualitative study with women with gynaecological cancer. Aust N Z J Obstet Gynaecol (2006) 0.75
Maxillomandibular distraction osteogenesis advancement for the treatment of obstructive sleep apnea. J Oral Maxillofac Surg (2007) 0.75
Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases. Int J Gynecol Cancer (2016) 0.75